文献速递肺结节与肺癌

游离DNA片段组学在有肺癌症状患者诊断评估中的应用

Cell-Free DNA Fragmentomes in the Diagnostic Evaluation of Patients With Symptoms Suggestive of Lung Cancer.
PubMed 文献 · Chest · 2023-04-26

该研究纳入296例因初始影像异常和肺癌相关症状转诊至哥本哈根Bispebjerg医院的成人,检测血浆cfDNA片段组学(DELFI评分)。肺癌患者(n=98)中位DELFI评分高于无癌者(n=198;0.94 vs 0.19;P < .001),校正年龄、吸烟史和症状后DELFI评分改善肺癌预测(AUC 0.74-0.94),优于可疑症状区分肺癌与无癌者。

要点

  • 肺癌患者中位DELFI评分0.94,显著高于无癌者0.19(P < .001)。
  • 校正年龄、吸烟史和症状后,DELFI评分改善肺癌预测(AUC 0.74-0.94)。
  • DELFI评分区分肺癌与无癌者优于可疑症状,支持片段组学生物标志物用于诊断。

核心结论

  • DELFI评分区分肺癌患者与无癌者优于可疑症状。
  • 基于片段组学的生物标志物方法可能有助于有肺癌可疑症状患者的诊断解决。

研究设计与样本

  • 研究纳入因初始影像异常和符合肺癌的症状转诊至Bispebjerg医院(丹麦哥本哈根)的成人。
  • 从诊断前访视获取的血浆样本中分离cfDNA,进行测序并分析全基因组cfDNA片段模式。
  • 共分析296例个体,其中肺癌98例,无癌198例。

主要发现

  • 肺癌患者中位DELFI评分为0.94,无癌者为0.19(P < .001)。
  • 在校正年龄、吸烟史和就诊症状的多变量模型中,加入DELFI评分改善了有症状者的肺癌预测(AUC 0.74-0.94)。

临床怎么用

  • 对于有肺癌可疑症状的患者,可考虑采用基于cfDNA片段组学的DELFI评分辅助诊断评估。
  • DELFI评分可能优于仅凭可疑症状判断肺癌可能性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The diagnostic workup of individuals suspected of having lung cancer can be complex and protracted because conventional symptoms of lung cancer have low specificity and sensitivity. RESEARCH QUESTION: Among individuals with symptoms of lung cancer, can a blood-based approach to analyze cell-free DNA (cfDNA) fragmentation (the DNA evaluation of fragments for early interception [DELFI] score) enhance evaluation for the possible presence of lung cancer? STUDY DESIGN AND METHODS: Adults were referred to Bispebjerg Hospital (Copenhagen, Denmark) for diagnostic evaluation of initial imaging anomalies and symptoms consistent with lung cancer. Numbers and types of symptoms were extracted from medical records. cfDNA from plasma samples obtained at the prediagnostic visit was isolated, sequenced, and analyzed for genome-wide cfDNA fragmentation patterns. The relationships among clinical presentation, cancer status, and DELFI score were examined. RESULTS: A total of 296 individuals were analyzed. Median DELFI scores were higher for those with lung cancer (n = 98) than those without cancer (n = 198; 0.94 vs 0.19; P < .001). In a multivariate model adjusted for age, smoking history, and presenting symptoms, the addition of the DELFI score improved the prediction of lung cancer for those who demonstrated symptoms (area under the receiver operating characteristic curve, 0.74-0.94). INTERPRETATION: The DELFI score distinguishes individuals with lung cancer from those without cancer better than suspicious symptoms do. These results represent proof-of-concept support that fragmentation-based biomarker approaches may facilitate diagnostic resolution for patients with concerning symptoms of lung cancer.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Leal AIC, Mathios D, Jakubowski D, et al. Cell-Free DNA Fragmentomes in the Diagnostic Evaluation of Patients With Symptoms Suggestive of Lung Cancer. Chest. 2023. PMID: 37116747. doi:10.1016/j.chest.2023.04.033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。